Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
Stopped early
Conditions studied: Choroidal Melanoma, Indeterminate Lesions
In brief
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.
Key facts
- Study ID
- NCT05266430
- Run by
- Aura Biosciences
- People needed
- 2
- Starts
- 2022-04-14
- Expected to finish
- 2023-04-20
- Last updated by the study team
- 2023-08-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Wisconsin Dept of Ophthalmology & Visual Sciences — Madison, Wisconsin, United States
- Associated Retinal Consultants, P.C. — Royal Oak, Michigan, United States
- Oregon Health & Science University Casey Eye Institute — Portland, Oregon, United States
- Retina Consultants of Carolina, PA — Greenville, South Carolina, United States
- St. Thomas Health/Tennessee Retina, P.C. — Nashville, Tennessee, United States
- Retina Consultants of Texas — Bellaire, Texas, United States
- Texas Retina Associates — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.